Research
Alzheimer's Research Changes Direction – Towards Combination Therapies
Article no. 26 · May 17, 2026 · Updated September 20, 2026 ·
The more researchers learn about Alzheimer's, the clearer it becomes that the disease is not about a single mechanism. Inflammation, energy deficiency, vascular problems, neurotransmitters, and protein accumulations influence each other in a complex network. Therefore, combination therapies are now being discussed more seriously in international research. (This overview article was created with the help of Chat GPT)
Alzheimer's is being redefined. From long being considered a relatively isolated protein problem, researchers are now increasingly describing the disease as a complex systemic illness. This also changes the view on treatment. Instead of seeking a single solution, interest is now growing in combination therapies where several biological mechanisms are affected simultaneously.
For many years, research was dominated by the amyloid hypothesis — the idea that plaques in the brain were the central cause of the disease. But even though new antibody treatments have shown some effect, an increasing number of researchers are beginning to believe that this is likely only part of the picture.
In today's research, Alzheimer's is increasingly discussed as an interplay between several processes:
- amyloid and tau
- inflammation and microglia
- disrupted energy metabolism
- vascular problems
- insulin resistance
- impaired signaling between nerve cells.
Therefore, interest is now growing in combination therapies that target multiple goals simultaneously — similar to cancer or HIV treatment.
Researchers are discussing, among other things, combinations of:
- anti-amyloid and anti-tau